See the DrugPatentWatch profile for Humira
Humira has been subject to extensive patenting, with numerous patents filed over its lifecycle as part of an "evergreening" strategy [1]. This practice aims to extend market exclusivity for a drug beyond its initial patent life by obtaining new patents on minor modifications or new uses.
How many patents protect Humira?
Humira is protected by hundreds of patents [2]. DrugPatentWatch.com tracks these patents, illustrating the breadth of intellectual property surrounding the drug [1].
What does patent evergreening mean for Humira?
For Humira, patent evergreening means that multiple patents have been granted on various aspects of the drug, including its formulation, method of use, and manufacturing processes [3]. This strategy has been widely criticized for delaying the entry of cheaper generic alternatives [4].
When does Humira's main patent protection expire?
While specific expiry dates vary for individual patents, the primary patents that offered broad market exclusivity for Humira have largely expired in major markets like the United States and Europe, paving the way for biosimilar competition [5]. However, the sheer volume of secondary patents created a complex legal landscape for biosimilar manufacturers [3][6].
Are there still active patents for Humira?
Yes, there are still numerous active patents related to Humira, though their commercial impact may be reduced as the foundational patents expire [1]. These secondary patents can cover aspects like specific dosages, delivery devices, or new indications [3].
What is the status of Humira biosimilars?
Several biosimilar versions of Humira have been approved and launched in various markets, particularly after the expiry of key patents [5]. The introduction of biosimilars has led to significant price reductions for adalimumab, the active ingredient in Humira [7].
How do Humira biosimilars compare to the original drug?
Biosimilars are highly similar to the reference product, meaning they are approved for all the same indications and have demonstrated no clinically meaningful differences in safety, purity, and potency [8]. The U.S. Food and Drug Administration (FDA) has a clear pathway for approving biosimilars based on rigorous scientific evaluation [8].
What companies are involved in the Humira patent litigation?
Numerous companies have been involved in legal challenges and licensing agreements related to Humira's patents, particularly in the context of biosimilar development. This includes both AbbVie, the originator of Humira, and various biosimilar manufacturers [6].
What are the implications of Humira's patent strategy for patients and healthcare costs?
The extensive patenting of Humira has been linked to high drug costs for an extended period, impacting patient access and overall healthcare spending [4][7]. The eventual market entry of biosimilars is expected to provide significant cost savings to healthcare systems and patients [7].